EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Plasma Cell Myeloma

Interventions: Biological: Daratumumab
Drug: Bortezomib
Drug: Dexamethasone
Drug: Ixazomib

First Posted Date: 2019-05-08

Last Posted Date: 2024-06-21

Lead Sponsor: Emory University

Target Recruit Count: 49

Registration Number: NCT03942224

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Endoscopic vs. Suction Device Calibration in Sleeve Gastrectomy

Not Applicable

Completed

Conditions: Obesity
Gastrectomy

Interventions: Device: Esophagogastroduodenoscopy (EGD) calibration
Device: ViSiGi® 3D suction calibration device

First Posted Date: 2019-05-07

Last Posted Date: 2024-05-21

Lead Sponsor: Emory University

Target Recruit Count: 106

Registration Number: NCT03939819

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

Dialectical Behavior Therapy for Pregnant Women

Not Applicable

Completed

Conditions: Perinatal Depression

Interventions: Behavioral: Dialectical Behavior Therapy (DBT) Skills Training

First Posted Date: 2019-05-06

Last Posted Date: 2022-09-30

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT03938350

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States

In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)

Phase 3

Completed

Conditions: Hemostasis

Interventions: Drug: Fibrinogen Concentrate (FC)
Drug: Cryoprecipitate

First Posted Date: 2019-04-30

Last Posted Date: 2024-02-20

Lead Sponsor: Emory University

Target Recruit Count: 36

Registration Number: NCT03932240

Locations: 🇺🇸
Children's Healthcare of Atlanta (CHOA), Egleston, Atlanta, Georgia, United States

Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

Phase 2

Active, not recruiting

Conditions: Graft Versus Host Disease

Interventions: Drug: Abatacept

First Posted Date: 2019-04-23

Last Posted Date: 2024-04-19

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT03924401

Locations: 🇺🇸
University of Mississippi Medical Center, Children's Center for Cancer and Blood Disorders, Jackson, Mississippi, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Nemours/Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States

and more 6 locations

Primary-Care Based Mindfulness Intervention

Not Applicable

Completed

Conditions: Major Depressive Disorder
Post Traumatic Stress Disorder

Interventions: Behavioral: Mindfulness-Based Cognitive Therapy

First Posted Date: 2019-04-22

Last Posted Date: 2023-08-22

Lead Sponsor: Emory University

Target Recruit Count: 80

Registration Number: NCT03922581

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States

Cataract DME - Peri vs. Intraop

Phase 2

Withdrawn

Conditions: Diabetic Macular Edema
Cataract

Interventions: Drug: Aflibercept injected Pre- and Post-operatively
Drug: Aflibercept injected intraoperatively

First Posted Date: 2019-04-19

Last Posted Date: 2020-12-24

Lead Sponsor: Emory University

Registration Number: NCT03920878

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
Emory Clinic, Atlanta, Georgia, United States

Ultrasound in Diagnosing Patients With Skin Lesions

Not Applicable

Completed

Conditions: Skin Lesion

Interventions: Procedure: Ultrasound

First Posted Date: 2019-04-16

Last Posted Date: 2024-01-30

Lead Sponsor: Emory University

Target Recruit Count: 47

Registration Number: NCT03914846

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Unresectable Pancreatic Adenocarcinoma
Recurrent Pancreatic Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8
Stage IV Pancreatic Cancer AJCC v8

Interventions: Drug: Gemcitabine
Drug: Nab-paclitaxel
Drug: Telotristat Ethyl

First Posted Date: 2019-04-10

Last Posted Date: 2023-08-29

Lead Sponsor: Emory University

Target Recruit Count: 22

Registration Number: NCT03910387

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Structured Function-Based Elopement Treatment Program

Not Applicable

Completed

Conditions: Autism Spectrum Disorder

Interventions: Behavioral: Parent Education Program (PEP)
Behavioral: Function-Based Elopement Treatment (FBET)

First Posted Date: 2019-04-02

Last Posted Date: 2023-08-08

Lead Sponsor: Emory University

Target Recruit Count: 76

Registration Number: NCT03899831

Locations: 🇺🇸
Marcus Autism Center, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy